| CAT # | Product Name | Tsanangudzo |
| CPD100587 | Phlorizin | Phlorizin, inonziwo phloridzin, inonzi glucoside ye phloretin, dihydrochalcone, mhuri ye bicyclic flavonoids, iyo inozoitawo boka diki mune dzakasiyana siyana phenylpropanoid synthesis nzira muzvirimwa. Phlorizin inokwikwidza inhibitor yeSGLT1 uye SGLT2 nokuti inokwikwidzana neD-glucose yekubatanidza kune mutakuri; izvi zvinoderedza renal glucose kutakura, kuderedza huwandu hweglucose muropa. Phlorizin yakadzidzwa semushonga ungangoita kurapa chirwere cheshuga cherudzi rwechipiri, asi kubva ipapo yakatsiviwa nemamwe anosarudzika uye anonyanya kuvimbisa analog ekugadzira, akadai secanagliflozin uye dapagliflozin. |
| CPD0045 | Ipragliflozin | Ipragliflozin, inozivikanwawo seASP1941, ine simba uye inosarudza SGLT2 inhibitor yekurapa chirwere cheshuga chechipiri. Ipragliflozin kurapwa kwakavandudza glycemic control kana yawedzerwa kumetformin therapy uye inogona kuve yakabatana nekuremerwa uye kuderedzwa kweropa kana ichienzaniswa ne placebo. Ipragliflozin inonatsiridza kwete hyperglycemia chete asiwo chirwere cheshuga / kufutisa-kwakabatana nemetabolism abnormalities mumhando 2 chirwere cheshuga mbeva. Yakabvumidzwa kushandiswa muJapan muna 2014 |
| CPD100585 | Tofogliflozin | Tofogliflozin, inozivikanwawo seCSG 452, ine simba uye yakasarudzika yakasarudzika SGLT2 inhibitor pasi pekuvandudzwa kurapwa kwechirwere cheshuga mellitus. Tofogliflozin inovandudza glycemic control uye inoderedza uremu hwemuviri kune varwere vane Type 2 chirwere cheshuga mellitus. Tofogliflozin dose-inotsamira yakadzvanya glucose kupinda mu tubular masero. High glucose exposure (30?mM) ye4 uye 24?h zvakanyanya kuwedzera oxidative kusagadzikana chizvarwa mumasero e-tubular, ayo akadzvinyirirwa nekurapa kwe tofogliflozin kana an antioxidant N-acetylcysteine (NAC). |
| CPD100583 | Empagliflozin | Empagliflozin, inozivikanwawo seBI10773 (zita rekutengesa Jardiance), mushonga wakatenderwa kurapa chirwere cheshuga cherudzi rwechipiri muvanhu vakuru muna 2014. Yakagadzirwa naBoehringer Ingelheim naEli Lilly and Company. Empagliflozin inhibitor ye sodium glucose co-transporter-2 (SGLT-2), uye inoita kuti shuga iri muropa ibatwe neitsvo uye ichibviswa muweti. Empagliflozin inhibitor yesodium glucose co-transporter-2 (SGLT-2), iyo inowanikwa chete muproximal tubules yenephronic zvikamu muitsvo. SGLT-2 inoverengera nezve 90 muzana yeglucose reabsorption muropa. |
| CPD100582 | Kanagliflozin | Canagliflozin (INN, zita rekutengesa Invokana) mushonga wekurapa chirwere cheshuga chechipiri. Yakagadzirwa neMitsubishi Tanabe Pharma uye inotengeswa pasi perezinesi naJanssen, chikamu cheJohnson & Johnson. Canagliflozin inhibitor ye subtype 2 sodium-glucose transport protein (SGLT2), iyo inokonzera inosvika 90% yeglucose reabsorption muitsvo. Kuvhara mutakuri uyu kunoita kuti glucose yeropa ibviswe kuburikidza weti. Muna Kurume 2013, canagliflozin yakava yekutanga SGLT2 inhibitor kubvumidzwa muUnited States. |
| CPD0003 | Dapagliflozin | Dapagliflozin, inozivikanwawo seBMS-512148, mushonga unoshandiswa kurapa chirwere cheshuga cherudzi rwechipiri chakabvumidzwa muna 2012 neFDA. Dapagliflozin inhibits subtype 2 ye sodium-glucose transport mapuroteni (SGLT2) ayo anokonzeresa angangoita 90% yeglucose reabsorption muitsvo. Kuvhara iyi nzira yekutakura kunoita kuti glucose yeropa ibviswe kuburikidza weti. Mumiyedzo yekiriniki, dapagliflozin yakadzikisa HbA1c ne 0.6 maringe ne placebo percentage point kana yawedzerwa ku metformin. |
